Carisoprodol

Carisoprodol Tablets have sedative properties (in the low back pain trials, 13% to 17% of patients who received Carisoprodol Tablets experienced sedation compared to 6% of patients who received placebo) [see ADVERSE REACTIONS (6.1) ] and may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a motor vehicle or operating machinery. There have been post-marketing reports of motor vehicle accidents associated with the use of Carisoprodol Tablets.

Since the sedative effects of Carisoprodol Tablets and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously.

In the postmarketing experience with Carisoprodol Tablets, cases of dependence, withdrawal, and abuse have been reported with prolonged use. Most cases of dependence, withdrawal, and abuse occurred in patients who have had a history of addiction or who used Carisoprodol Tablets in combination with other drugs with abuse potential. However, there have been post-marketing adverse event reports of Carisoprodol Tablets-associated abuse when used without other drugs with abuse potential. Withdrawal symptoms have been reported following abrupt cessation after prolonged use. To reduce the chance of Carisoprodol Tablets dependence, withdrawal, or abuse, Carisoprodol Tablets should be used with caution in addiction-prone patients and in patients taking other CNS depressants including alcohol, and Carisoprodol Tablets should not be used more than two to three weeks for the relief of acute musculoskeletal discomfort.

Carisoprodol Tablets and one of its metabolites, meprobamate (a controlled substance), may cause dependence [see CLINICAL PHARMACOLOGY  12.3) ].

There have been postmarketing reports of seizures in patients who received Carisoprodol Tablets.  Most of these cases have occurred in the setting of multiple drug overdoses (including drugs of abuse, illegal drugs, and alcohol) [see OVERDOSAGE (10)].

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in practice. 

The data described below are based on 1387 patients pooled from two double blind, randomized, multicenter, placebo controlled, one-week trials in adult patients with acute, mechanical, lower back pain [see CLINICAL STUDIES (14) ].  In the study, patients were treated with 350 mg of Carisoprodol Tablets, or placebo three times a day and at bedtime for seven days.  The mean age was about 41 years old with 54% females and 46% males and 74% Caucasian, 16% Black, 9% Asian, and 2% other.

There were no deaths and there were no serious adverse reactions in the trial.  In the study, 2.7%, 2%, and 5.4 %, of patients treated with placebo and 350 mg of Carisoprodol Tablets, respectively, discontinued due to adverse events; and 0.5%, 0.5%, and 1.8% of patients treated with placebo and 350 mg of Carisoprodol Tablets, respectively, discontinued due to central nervous system adverse reactions.

Table 1 displays adverse reactions reported with frequencies greater than 2% and more frequently than placebo in patients treated with Carisoprodol Tablets in the trial described above.

Table 1 – Patients with Adverse Reactions in Controlled Studies

The following events have been reported during postapproval use of Carisoprodol Tablets.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular: Tachycardia, postural hypotension, and facial flushing [see OVERDOSAGE (10) ].

Central Nervous System:  Drowsiness, dizziness, vertigo, ataxia, tremor, agitation, irritability, headache, depressive reactions, syncope, insomnia, and seizures [see OVERDOSAGE (10) ].

Gastrointestinal:  Nausea, vomiting, and epigastric discomfort.

Hematologic:  Leukopenia, pancytopenia.

The sedative effects of Carisoprodol Tablets and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of Carisoprodol Tablets and meprobamate, a metabolite of Carisoprodol Tablets, is not recommended [see WARNINGS AND PRECAUTIONS  (5.1)].

Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate [see CLINICAL PHARMACOLOGY (12.3)]. Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with Carisoprodol Tablets could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John's Wort, with Carisoprodol Tablets could result in decreased exposure of carisoprodol and increased exposure of meprobamate. Low dose aspirin also showed induction effect on CYP2C19. The full pharmacological impact of these potential alterations of exposures in terms of either efficacy or safety of Carisoprodol Tablets is unknown.

There are no data on the use of Carisoprodol Tablets during human pregnancy.  Animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival.  The primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic.  Retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increased risk for particular congenital malformations.

Teratogenic effects:  Animal studies have not adequately evaluated the teratogenic effects of carisoprodol.  There was no increase in the incidence of congenital malformations noted in reproductive studies in rats, rabbits, and mice treated with meprobamate.  Retrospective, post-marketing studies of meprobamate during human pregnancy were equivocal for demonstrating an increased risk of congenital malformations following first trimester exposure.  Across studies that indicated an increased risk, the types of malformations were inconsistent.

Nonteratogenic effects:  In animal studies, carisoprodol reduced fetal weights, postnatal weight gain, and postnatal survival at maternal doses equivalent to 1-1.5 times the human dose (based on a body surface area comparison).  Rats exposed to meprobamate in-utero showed behavioral alterations that persisted into adulthood.  For children exposed to meprobamate in-utero, one study found no adverse effects on mental or motor development or IQ scores.  Carisoprodol Tablets should be used during pregnancy only if the potential benefit justifies the risk to the fetus.

There is no information about the effects of Carisoprodol Tablets on the mother and the fetus during labor and delivery.

Very limited data in humans show that Carisoprodol Tablets is present in breast milk and may reach concentrations two to four times the maternal plasma concentrations. In one case report, a breast-fed infant received about 4-6% of the maternal daily dose through breast milk and experienced no adverse effects.  However, milk production was inadequate and the baby was supplemented with formula.  In lactation studies in mice, female pup survival and pup weight at weaning were decreased.  This information suggests that maternal use of Carisoprodol Tablets may lead to reduced or less effective infant feeding (due to sedation) and/or decreased milk production.  Caution should be exercised when Carisoprodol Tablets are administered to a nursing woman.

The efficacy, safety, and pharmacokinetics of Carisoprodol Tablets in pediatric patients less than 16 years of age have not been established.

The efficacy, safety, and pharmacokinetics of Carisoprodol Tablets in patients over 65 years old have not been established.

The safety and pharmacokinetics of Carisoprodol Tablets in patients with renal impairment have not been evaluated. Since Carisoprodol Tablets are excreted by the kidney, caution should be exercised if Carisoprodol Tablets are administered to patients with impaired renal function. Carisoprodol is dialyzable by hemodialysis and peritoneal dialysis.

The safety and pharmacokinetics of Carisoprodol Tablets in patients with hepatic impairment have not been evaluated.  Since Carisoprodol Tablets are metabolized in the liver, caution should be exercised if Carisoprodol Tablets are administered to patients with impaired hepatic function.

Patients with reduced CYP2C19 activity have higher exposure to carisoprodol.  Therefore, caution should be exercised in administration of Carisoprodol Tablets to these patients [see CLINICAL PHARMACOLOGY (12.3)].

The mechanism of action of carisoprodol in relieving discomfort associated with acute painful musculoskeletal conditions has not been clearly identified.

In animal studies, muscle relaxation induced by carisoprodol is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.

Carisoprodol is a centrally acting skeletal muscle relaxant that does not directly relax skeletal muscles. 

A metabolite of carisoprodol, meprobamate, has anxiolytic and sedative properties.  The degree to which these properties of meprobamate contribute to the safety and efficacy of Carisoprodol Tablets is unknown.

The pharmacokinetics of carisoprodol and its metabolite meprobamate were studied in a crossover study of 24 healthy subjects (12 male and 12 female) who received single doses of 350 mg Carisoprodol Tablets (see Table 2). The C_max of meprobamate was 2.5 ± 0.5 µg/mL (mean ± SD) after administration of a single 350 mg dose of Carisoprodol Tablets, which is approximately 30% of the C_max of meprobamate (approximately 8 µg/mL) after administration of a single 400 mg dose of meprobamate.

Table 2. Pharmacokinetic Parameters of Carisoprodol and Meprobamate (Mean ± SD, n=24)

Absorption:  Absolute bioavailability of carisoprodol has not been determined.  The mean time to peak plasma concentrations (T_max) of carisoprodol was approximately 1.5 to 2 hours.  Co-administration of a high-fat meal with Carisoprodol Tablets (350 mg tablet) had no effect on the pharmacokinetics of carisoprodol.  Therefore, Carisoprodol Tablets may be administered with or without food.

Metabolism:  The major pathway of carisoprodol metabolism is via the liver by cytochrome enzyme CYP2C19 to form meprobamate.  This enzyme exhibits genetic polymorphism (see Patients with Reduced CYP2C19 Activity below).

Elimination:  Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.  The half-life of meprobamate is approximately 10 hours.

Gender:  Exposure of carisoprodol is higher in female than in male subjects (approximately 30-50% on a weight adjusted basis).  Overall exposure of meprobamate is comparable between female and male subjects.

Patients with Reduced CYP2C19 Activity:  Carisoprodol Tablets should be used with caution in patients with reduced CYP2C19 activity.  Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol, and concomitant 50% reduced exposure to meprobamate compared to normal CYP2C19 metabolizers.  The prevalence of poor metabolizers in Caucasians and African Americans is approximately 3 - 5% and in Asians is approximately 15 - 20%.

Long term studies in animals have not been performed to evaluate the carcinogenic potential of carisoprodol. 

Carisoprodol Tablets were not formally evaluated for genotoxicity.  In published studies, carisoprodol was mutagenic in the in vitro mouse lymphoma cell assay in the absence of metabolizing enzymes, but was not mutagenic in the presence of metabolizing enzymes.  Carisoprodol was clastogenic in the in vitro chromosomal aberration assay using Chinese hamster ovary cells with or without the presence of metabolizing enzymes.  Other types of genotoxic tests resulted in negative findings.  Carisoprodol was not mutagenic in the Ames reverse mutation assay using S. typhimurium strains with or without metabolizing enzymes, and was not clastogenic in an in vivo mouse micronucleus assay of circulating blood cells.

Carisoprodol Tablets were not formally evaluated for effects on fertility.  Published reproductive studies of carisoprodol in mice found no alteration in fertility although an alteration in reproductive cycles characterized by a greater time spent in estrus was observed at a carisoprodol dose of 1200 mg/kg/day.  In a 13-week toxicology study that did not determine fertility, mouse testes weight and sperm motility were reduced at a dose of 1200 mg/kg/day.  In both studies, the no effect level was 750 mg/kg/day, corresponding to approximately 2.6 times the human equivalent dosage of 350 mg four times a day, based on a body surface area comparison.  The significance of these findings for human fertility is not known.

Patients should be advised that Carisoprodol Tablets may cause drowsiness and/or dizziness, and has been associated with motor vehicle accidents. Patients should be advised to avoid taking Carisoprodol Tablets before engaging in potentially hazardous activities such as driving a motor vehicle or operating machinery [see WARNINGS AND PRECAUTIONS   (5.1)].

Patients should be advised to avoid alcoholic beverages while taking Carisoprodol Tabletsl and to check with their doctor before taking other CNS depressants such as benzodiazepines, opioids, tricyclic antidepressants, sedating antihistamines, or other sedatives [see WARNINGS AND PRECAUTIONS  (5.1) ].

Patients should be advised that treatment with Carisoprodol Tablets should be limited to acute use (up to two or three weeks) for the relief of acute, musculoskeletal discomfort. In the post-marketing experience with Carisoprodol Tablets, cases of dependence, withdrawal and abuse have been reported with prolonged use. If the musculoskeletal symptoms still persist, patients should contact their healthcare provider for further evaluation.

To report SUSPECTED ADVERSE REACTIONS, contact West-ward Pharmaceutical Corp. at 1-877-233-2001, or FDA at 1-800-1088 or www.fda.gov/medwatch.

Manufactured by:
West-ward Pharmaceutical CorpEatontown, NJ 07724

Revised January 2012

Repacked by:

H.J. Harkins Company, Inc.

Grover Beach, CA 93433